Omeprazole

Čo je Omeprazole?

Omeprazole is a proton pump inhibitor (PPI) — a widely prescribed class of medicines that reduces the production of stomach acid. It is approved by the European Medicines Agency (EMA) for the treatment of acid-related conditions including gastro-oesophageal reflux disease (GERD), peptic ulcers, and Helicobacter pylori eradication. Low-dose formulations are available without a prescription in many EU countries for short-term use.

Ako funguje Omeprazole?

Omeprazole is a prodrug that is activated in the acidic environment of the stomach’s parietal cells. Once activated, it covalently binds to and irreversibly inhibits the H⁺/K⁺-ATPase enzyme (the proton pump) — the final common pathway for acid secretion into the stomach lumen:

• Acid secretion blockade: By inhibiting the proton pump, Omeprazole reduces gastric acid secretion regardless of the stimulus (food, histamine, gastrin, or acetylcholine). This is more complete acid suppression than H2-receptor antagonists (e.g., ranitidine, famotidine).
• Healing of mucosal damage: Reduced gastric acidity allows the oesophageal and gastric mucosa to heal, which is particularly important in reflux oesophagitis and peptic ulceration.
• H. pylori eradication support: Omeprazole raises intragastric pH to a level at which antibiotic activity against H. pylori is enhanced, making PPI-based triple therapy effective.
• Accumulation over days: Because Omeprazole inhibits only active pumps, and new pumps are continuously synthesised, maximum acid suppression builds up over the first 3–5 days of daily dosing rather than occurring after the first dose.

Pre koho je určený/á Omeprazole?

Omeprazole is indicated for:

• Gastro-oesophageal reflux disease (GERD): Including reflux oesophagitis, symptomatic GERD without oesophagitis, and maintenance to prevent relapse.
• Peptic ulcer disease: Treatment of gastric ulcers and duodenal ulcers, including prevention of NSAID-associated ulcers in high-risk patients.
• Helicobacter pylori eradication: In combination with two antibiotics (typically clarithromycin and amoxicillin or metronidazole) to cure H. pylori infection and reduce ulcer recurrence.
• Zollinger-Ellison syndrome: A rare condition of pathological gastric acid hypersecretion requiring high-dose PPI therapy.
• Self-treatment of heartburn: Low-dose (10–20 mg) OTC use in adults for occasional heartburn, for up to 14 days in many EU countries.

Omeprazole is not appropriate as a substitute for investigation when:

• Symptoms could indicate serious upper GI pathology (dysphagia, unexplained weight loss, persistent vomiting, bleeding)
• Alarm symptoms are present — these warrant urgent gastroenterological assessment

Dávkovanie

Dosage varies by indication and patient factors. Standard EMA-approved dosing for adults:

Indication	Dose	Duration
Symptomatic GERD (no oesophagitis)	20 mg once daily	4 weeks
Reflux oesophagitis	20–40 mg once daily	4–8 weeks
GERD maintenance	10–20 mg once daily	Ongoing (with review)
Duodenal ulcer	20 mg once daily	4 weeks
Gastric ulcer	20–40 mg once daily	4–8 weeks
H. pylori eradication (triple therapy)	20 mg twice daily	7 days (with antibiotics)
NSAID-associated ulcer prevention	20 mg once daily	Duration of NSAID use
Short-term heartburn (OTC)	10–20 mg once daily	Up to 14 days

Omeprazole should be taken before eating, ideally 30–60 minutes before breakfast. Capsules should be swallowed whole; if swallowing is difficult, they can be opened and the pellets mixed with a small amount of acidic liquid (e.g., fruit juice) but should not be chewed.

Vedľajšie účinky

Omeprazole is generally well tolerated. Most side effects are mild and uncommon.

Common side effects (may affect up to 1 in 10 people)

• Headache
• Abdominal pain
• Diarrhoea
• Nausea
• Flatulence
• Constipation

Less common but important side effects

• Hypomagnesaemia: Low serum magnesium, particularly with long-term use (more than 3 months). Can cause muscle cramps, fatigue, tetany, and cardiac arrhythmias. Magnesium levels should be checked in patients on long-term PPI therapy.
• Vitamin B12 deficiency: Reduced gastric acid impairs B12 absorption from food. Risk increases with long-term use.
• Clostridium difficile (C. diff) colitis: Gastric acid provides a barrier to intestinal infection; PPI use is associated with a modestly increased risk of C. difficile colitis, particularly in hospital settings.
• Bone fractures: Long-term high-dose use has been associated with a modestly increased risk of osteoporotic fractures, possibly due to reduced calcium absorption.
• Interstitial nephritis: Rare but serious kidney inflammation associated with PPI use; often presents with non-specific symptoms.
• Subacute cutaneous lupus erythematosus (SCLE): Rare skin reaction associated with proton pump inhibitors; resolves on discontinuation.

Omeprazole vs alternatívy

Medicine	Class	Onset	Acid Suppression	Key Feature
Omeprazole	PPI	3–5 days for max effect	Highest (irreversible pump inhibition)	Generic; widely available OTC at low doses
Lansoprazole	PPI	3–5 days for max effect	High	Generally similar efficacy; some prefer tolerability profile
Pantoprazole	PPI	3–5 days for max effect	High	Fewer drug interactions (less CYP2C19 dependence)
Esomeprazole	PPI	3–5 days for max effect	Slightly higher in some studies	S-isomer of omeprazole; often similar clinical outcomes
Famotidine	H2 receptor antagonist	1–3 hours	Moderate	Faster but less complete acid suppression; useful for on-demand relief

Hlavné rozdiely:

• Omeprazole vs Lansoprazole: Both are PPIs with similar clinical efficacy. Lansoprazole may be preferred by patients who experience side effects with omeprazole. Generic availability makes both cost-effective.
• Omeprazole vs H2 antagonists: H2 antagonists (famotidine) act faster but achieve less complete acid suppression. Tolerance (tachyphylaxis) develops to H2 antagonists over time; it does not occur with PPIs. PPIs are preferred for healing oesophagitis and H. pylori eradication; H2 antagonists may be useful for on-demand heartburn relief.

Ako získať Omeprazole online v Európe

Low-dose Omeprazole (10–20 mg) is available over the counter for short-term heartburn treatment in many EU member states. Higher doses and longer treatment courses require a prescription from a qualified medical professional.

Prescrivia pôsobí ako technologický sprostredkovateľ: nepredpisujeme lieky, nezamestnávame lekárov ani nepredávame lieky. Naša platforma spája pacientov s nezávislými lekármi registrovanými v EÚ, ktorí môžu vykonávať dôverné online zdravotné posúdenia.

Postup je nasledovný:

1. Vyplňte zdravotný dotazník: Answer structured health questions about your digestive symptoms, medical history, and current medications. This assessment is reviewed by an independent doctor.
2. Posúdenie lekárom: An independent EU-registered doctor reviews your assessment. If prescription Omeprazole is clinically appropriate, they may issue a prescription. If not, the doctor will explain why.
3. Predpis a vybavenie: If a prescription is issued, it is sent to a licensed EU pharmacy partner, which dispenses and ships the medicine directly to you.

Dôležité: Prescrivia nezaručuje, že bude predpis vystavený. Všetky rozhodnutia o predpisovaní vykonávajú nezávisle kvalifikovaní odborní lekári na základe Vašich individuálnych klinických okolností.

Dôležité bezpečnostné informácie

Seek urgent medical attention if you experience:

• Difficulty swallowing or pain when swallowing
• Unintentional weight loss
• Vomiting blood or material that looks like coffee grounds
• Black, tarry stools
• Persistent severe abdominal pain

These may be signs of serious upper gastrointestinal disease that requires investigation beyond PPI treatment.

Informujte svojho lekára pred začatím užívania Omeprazole ak máte:

• Liver disease (Omeprazole is extensively metabolised by the liver)
• Kidney disease
• Osteoporosis or at risk of bone fractures
• A history of hypomagnesaemia
• Lupus

Liekové interakcie: Omeprazole is metabolised by CYP2C19. It may reduce the antiplatelet effect of clopidogrel (an important interaction for patients with cardiovascular disease). It may also increase plasma levels of medicines metabolised by CYP2C19 (e.g., diazepam, phenytoin). Omeprazole may reduce the absorption of medicines requiring an acidic environment (e.g., itraconazole, atazanavir, erlotinib). Disclose all current medicines to your doctor.

Zdroje

Lekárske informácie na tejto stránke vychádzajú z nasledujúcich zdrojov:

• European Medicines Agency (EMA). Losec (omeprazole) — Summary of Product Characteristics. Available at: ema.europa.eu
• World Health Organization (WHO). WHO Model List of Essential Medicines — Gastrointestinal section. who.int
• Malfertheiner P, et al. Management of Helicobacter pylori infection — the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.
• Vaezi MF, et al. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35–48.

Tento obsah je pravidelne prehodnocovaný s ohľadom na aktualizované klinické usmernenia. Je poskytovaný len na informačné účely a nepredstavuje lekárske poradenstvo. Vždy sa poraďte s kvalifikovaným zdravotníckym pracovníkom o rade týkajúcej sa Vašich individuálnych zdravotných okolností.